Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 14Leukemia, Myeloid, Acute 13Lymphoma 12Neoplasm Metastasis 11Pancreatic Neoplasms 9Prostatic Neoplasms 8Myelodysplastic Syndromes 8Burkitt Lymphoma 8Breast Neoplasms 8Glioma 7Colorectal Neoplasms 7Sarcoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Wilms Tumor 4Squamous Cell Carcinoma of Head and Neck 4Rhabdoid Tumor 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lung Neoplasms 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4

Interventions

Carboplatin 11atezolizumab 10Etoposide 9durvalumab 6Topotecan 6PM 01183 6Specimen Handling 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Irinotecan 2Injections 2Drug Therapy 2Cisplatin 2Biopsy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1berzosertib 1avelumab 1arginine decarboxylase 1amrubicin 1Vaccines 1Taxes 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Biopsy × 30 days × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03896503 2026-06-01

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

National Cancer Institute (NCI)

Phase 2 Active not recruiting
104 enrolled 22 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡